Vcreate is building a platform to accelerate the development of T-cell receptor (TCR) based therapies. TCR based therapies offer a promising alternative to CAR-T for solid tumors and other diseases, but identifying clinically relevant TCRs usually takes years and costs millions of dollars. We aim to dramatically reduce this development time -- from years to weeks -- through our novel TCR screening assays and machine learning models.
Investors 3
| Date | Name | Website |
| 16.06.2021 | MBC BioLab... | mbcbiolabs... |
| - | North Sout... | northsouth... |
| - | Merck Digi... | mds.studio |